US 12,064,473 B2
Cancer vaccines targeting Survivin and uses thereof
Jian Yan, Wallingford, PA (US); Anna Slager, Lansdale, PA (US); Bradley Garman, Glenside, PA (US); and Neil Cooch, Oreland, PA (US)
Assigned to Inovio Pharmaceuticals, Inc., Plymouth Meeting, PA (US)
Filed by Inovio Pharmaceuticals, Inc., Plymouth Meeting, PA (US)
Filed on Dec. 13, 2018, as Appl. No. 16/219,520.
Claims priority of provisional application 62/598,267, filed on Dec. 13, 2017.
Prior Publication US 2019/0175707 A1, Jun. 13, 2019
Int. Cl. G01N 31/00 (2006.01); A61K 39/00 (2006.01); A61K 39/39 (2006.01); A61P 35/00 (2006.01); C07K 16/40 (2006.01); C12N 15/52 (2006.01); C12N 15/62 (2006.01); G01N 33/53 (2006.01)
CPC A61K 39/00115 (2018.08) [A61K 39/39 (2013.01); A61P 35/00 (2018.01); C07K 16/40 (2013.01); C12N 15/52 (2013.01); C12N 15/62 (2013.01); A61K 2039/53 (2013.01); A61K 2039/55527 (2013.01); A61K 2039/575 (2013.01)] 2 Claims
 
1. A nucleic acid molecule comprising one or more nucleic acid sequences selected from the group consisting of:
(a) a nucleic acid sequence that encodes SEQ ID NO:11;
(b) a nucleic acid sequence that encodes SEQ ID NO:12;
(c) a nucleic acid sequence that encodes SEQ ID NO:13;
(d) a nucleic acid sequence that encodes a protein that is at least 95% identical to SEQ ID NO:11 and comprises SEQ ID NO: 5 and alanine at positions 33, 47, and 83 relative to SEQ ID NO: 11;
(e) a nucleic acid sequence that encodes a protein that is at least 95% identical to SEQ ID NO:12 and comprises SEQ ID NO: 5 and alanine at positions 33, 47, and 83 relative to SEQ ID NO: 12; and
(f) a nucleic acid sequence that encodes a protein that is at least 95% identical to SEQ ID NO: 13 and comprises SEQ TD NO: 5 and alanine at positions 33, 47, and 83 relative to SEQ ID NO: 13.